Reuters logo
GlaxoSmithKline seeks MDL for Zofran birth-defect cases
July 7, 2015 / 9:17 PM / 2 years ago

GlaxoSmithKline seeks MDL for Zofran birth-defect cases

(Reuters) - GlaxoSmithKline has asked a federal judicial panel to consolidate a dozen lawsuits alleging that its anti-nausea medication Zofran can cause birth defects in children born to women who took the drug while pregnant.

In a filing with the U.S. Judicial Panel on Multidistrict Litigation on Monday, the drugmaker said the cases should be transferred to federal court in Pennsylvania, where its U.S.-based operations are headquartered.

To read the full story on WestlawNext Practitioner Insights, click here: bit.ly/1Co2miN

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below